Cytori Therapeutics, Inc. (USA)
MultiStem cell therapy being developed by Athersys (NASDAQ: ATHX) has excited people because of the advantages and sophistication levels it possesses over existing stem cell therapies. Big pharma is betting on this new therapy; let us find out why.
MultiStem – not a cure-all but a relatively potent therapy
The popular belief is that since stem cell therapy is a cure-all therapy as it involves removing and replacement of the malfunctioning more »
By George S. Mack of The Life Sciences Report
For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.
I have been a critic of pharma’s absence from the stem cell industry. The major drug manufacturers have held on to the small-molecule business model for dear life, and now even after nearly 15 years of stagnation they still don’t seem more »
Let’s not fool ourselves, an insider knows what’s going to happen before it happens. They have a good grasp on sales, demand, supply, and other operational metrics that are vital to success. Therefore, when an insider purchases shares of his or her company, it might be a sign of what’s to come. Therefore, I am looking at a few top insider buys, along with one major institutional more »
Small biotech stocks are fun for many reasons. The companies often have noble causes. They aim to treat wretched diseases. And their shares sell for small prices. Sure, many run on borrowed money and spend years deep in red ink. But they give us the potential of a five-bagger, 10-bagger, or even better.
In the small-cap biotech world, profits are ephemeral, but dreams loom large. That’s why I’ve more »